Light Science Technologies' Injectaclad acquisition drives first major order

About this episode

Simon Deacon discusses Light Science Technologies' first major order following the acquisition of Injectaclad.

Light Science Technologies Holdings PLC (AIM:LST, FRA:9FD) CEO Simon Deacon tells Proactive's Stephen Gunnion that the company has landed its first order since acquiring Injectaclad — a £410,000 contract to supply fire protection materials for a five-storey residential building. Deacon explains what sets Injectaclad apart: it eliminates the need to remove a building's façade, making it around ten times cheaper and six to seven times faster than traditional remediation, with no disruption to residents. The commercial opportunity is substantial. The company is working with 11 installers nationwide, has a quoted pipeline of around £130 million, and is targeting a market of over 40,000 UK buildings requiring remedial fire protection work, with improving approval timelines from the Building Safety Regulator helping projects move faster. For more insights like this, visit Proactive’s YouTube channel, like the video, subscribe, and enable notifications so you never miss future updates. #LightScienceTechnologies #Injectaclad #FireSafety #Cladding #BuildingSafety #ConstructionUK #StockMarketNews #SmallCapStocks #Infrastructure #FireProtection #UKHousing #InvestorNews #CEOInterview

People in this episode

Host: Stephen Gunnion

Guest: Simon Deacon

Topics covered

• fire protection
• building safety
• investment opportunities
• construction
• remediation

Keywords

• Light Science Technologies
• Injectaclad
• fire protection materials
• remedial fire protection
• UK buildings

Mentioned in this episode

Organizations: Light Science Technologies Holdings PLC, Building Safety Regulator

Places: UK, Injectaclad

More episodes of Proactive - Interviews for investors

• Regan Capital CIO on bond market opportunities in a rising rate environment · June 12, 2026 · 6 min
• Light Science Technologies lifts capacity 50% with new SMT line and global client win · June 12, 2026 · 5 min
• Poolbeg Pharma launches POLB 001 TOPICAL trial to tackle CAR-T side effects · June 12, 2026 · 4 min
• Lumos Diagnostics expands FebriDx adoption across 100+ US healthcare sites with CLIA Waiver · June 11, 2026 · 8 min
• Flow Metals advances drill-ready Yukon gold project while expanding Copper exploration in B.C. · June 11, 2026 · 6 min
• Midstream energy sector positioned for growth as LNG and AI drive demand · June 11, 2026 · 7 min